AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics
GET POWR RATINGS... FREE!
AGE Stock Summary
- AGE's price/sales ratio is 46.3; that's higher than the P/S ratio of 96.01% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -0.41 for AgeX Therapeutics Inc; that's greater than it is for only 4.95% of US stocks.
- As for revenue growth, note that AGE's revenue has grown -67.47% over the past 12 months; that beats the revenue growth of just 2.49% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to AgeX Therapeutics Inc, a group of peers worth examining would be FLDM, FCEL, JAGX, REFR, and SWI.
- AGE's SEC filings can be seen here. And to visit AgeX Therapeutics Inc's official web site, go to www.agexinc.com.
AGE Valuation Summary
- AGE's EV/EBIT ratio is -5.4; this is 118.43% lower than that of the median Healthcare stock.
- AGE's EV/EBIT ratio has moved up 8 over the prior 34 months.
- Over the past 34 months, AGE's price/sales ratio has gone down 31.3.
Below are key valuation metrics over time for AGE.
AGE Stock Price Chart Interactive Chart >
AGE Price/Volume Stats
|Current price||$0.76||52-week high||$3.06|
|Prev. close||$0.75||52-week low||$0.52|
|Day high||$0.86||Avg. volume||828,453|
|50-day MA||$0.75||Dividend yield||N/A|
|200-day MA||$1.08||Market Cap||28.79M|
AgeX Therapeutics, Inc. (AGE) Company Bio
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
Most Popular Stories View All
AGE Latest News Stream
|Loading, please wait...|
AGE Latest Social Stream
View Full AGE Social Stream
Latest AGE News From Around the Web
Below are the latest news stories about AgeX Therapeutics Inc that investors may wish to consider to help them evaluate AGE as an investment opportunity.
Good morning, trader!
Welcome back to a new year, investor!
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
ALAMEDA, Calif., December 14, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today a research collaboration with the University of California, Irvine (UCI) to explore the therapeutic potential of exosomes and other extracellular vesicles produced by neural stem cells derived from AgeX pluripotent stem cells, with the goal of developing therapies to treat adverse neurocognitive effe
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
ALAMEDA, Calif., November 30, 2021--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that ImStem Biotechnology, Inc. ("ImStem"), a biopharmaceutical company developing human embryonic stem cell (ESC)-derived mesenchymal stem cells, has dosed the first U.S. multiple sclerosis (MS) patient with ImStem’s lead investigational drug candidate IMS001 at the Shepherd Center in Atlanta, GA. I
ALAMEDA, Calif., November 23, 2021--AgeX Therapeutics , Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 17, 2021 it received a letter (the "Deficiency Letter") from the staff of the NYSE American (the "Exchange") indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stock
AGE Price Returns